Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR
2024-519991-18-00Phase 4Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 4, randomised trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Mean reduction of DAS28-CRP from baseline to 12 months. Planned start Apr 2025; status: authorised.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-519991-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519991-18-00.